GregoryPKalemkerianMD

Oncology • Ann Arbor, MI

Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Kalemkerian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kalemkerian's full profile

Already have an account?

Office
1500 East Medical Center Dr
B1 Floor Cancer & Geriatrics Ctr Recp C
Ann Arbor, MI 48109
Phone+1 734-647-8902
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1989 - 1992
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1985 - 1989
Northwestern University The Feinberg School of MedicineClass of 1985

Certifications & Licensure

MI State Medical License 1993 - 2024
MD State Medical License 1989 - 1994
IL State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 2
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC Start of enrollment: 2002 Mar 01
Completed
Phase 2
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC Start of enrollment: 2007 Sep 01
Completed
Phase 2
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent Start of enrollment: 2016 Mar 15
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 05
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the Col...
Upal Basu Roy, Mary Beth Beasley, Richard Walter Cartun, David M Hwang, Fernando Lopez-Rios, Kearin Reid, Lesley A Souter, Christina B Ventura, Lynette M Sholl, Mark A...> ;Archives of Pathology & Laboratory Medicine. 2024 Apr 16
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Lin, J. J., Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, Christina S Baik, Daniel Sw Tan, Dae H Lee, Daniel Misch, Elena Garralda, Dong-Wan Kim, Anthonie J va...> ;Future Oncology. 2024 Feb 1
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Hye Ryun Kim, Mark M Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet K Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin ...> ;JTO Clinical and Research Reports. 2023 Nov 1
1 citations
A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Angel Qin, Leah Wells, Binu Malhotra, Shirish Gadgeel, Bryan J Schneider, Nithya Ramnath, John D Rice, Gregory P Kalemkerian> ;Clinical Lung Cancer. 2024 Mar 1
1 citations
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
Humera Khurshid, Nofisat Ismaila, Jessica Bian, Raetasha Dabney, Millie Das, Peter Ellis, Jill Feldman, Christine Hann, Swati Kulkarni, Janessa Laskin, Rami Manochakia...> ;Journal of Clinical Oncology. 2023 Dec 10
Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).
Antoinette J Wozniak, Bryan Schneider, Gregory P Kalemkerian, Bobby Daly, Wei Chen, Jaclyn Ventimiglia, Misako Nagasaka, Marjorie G Zauderer> ;Clinical Lung Cancer. 2023 Sep 1
1 citations
Lung Cancer in Armenia.
Davit Zohrabyan, Nune Karapetyan, Samvel Danielyan, Tatul Saghatelyan, Liana Safaryan, Samvel Bardakhchyan, Gevorg Tamamyan, Martin Harutyunyan, Marine Rushanyan, Goha...> ;Journal of Thoracic Oncology. 2023 Apr 1
1 citations
An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.
Garth W Strohbehn, Kamya Sankar, Angel Qin, Gregory P Kalemkerian> ;Expert Opinion on Pharmacotherapy. 2022 Oct 1
43 citations
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
F Griesinger, G Curigliano, M Thomas, V Subbiah, C S Baik, D S W Tan, D H Lee, D Misch, E Garralda, D-W Kim, A J van der Wekken, J F Gainor, L Paz-Ares, S V Liu, G P K...> ;Annals of Oncology. 2022 Nov 1
72 citations
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, Elena Garralda, Luis Paz-Ares, Pilar Garrido, Ernest Nadal, Jacqueline Vuky, Gilberto Lopes, Gregory P Kalemkerian,...> ;Nature Medicine. 2022 Aug 1
1 citations
Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer.
Angel Qin, Fatima Lima, Samantha Bell, Gregory P Kalemkerian, Bryan J Schneider, Nithya Ramnath, Madelyn Lew, Santhoshi Krishnan, Shariq Mohammed, Arvind Rao, Timothy ...> ;Scientific Reports. 2022 May 31
20 citations
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shiri...> ;Journal of the National Comprehensive Cancer Network. 2021 Apr 20
Characterization of pneumonia and other factors leading to poorer survival across all age groups in patients with non-small cell lung cancer (NSCLC).
Frank Weinberg, Lili Zhao, Niranjana Chellappa, Gregory P. Kalemkerian, Nithya Ramnath> ;Journal of Thoracic Disease. 2021 Feb 1
13 citations
A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Angel Qin, Ramesh Rengan, Sylvia Lee, Rafael Santana-Davila, Bernardo H. L. Goulart, Renato G. Martins, Christina S. Baik, Gregory P. Kalemkerian, Khaled A. Hassan, Br...> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Sep 1
4 citations
Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Haritha G. Reddy, Angel Qin, Gregory P. Kalemkerian> ;Expert Opinion on Emerging Drugs. 2020 Aug 4
332 citations
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 ...
Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hs...> ;Journal of Clinical Oncology. 2020 May 29
15 citations
Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
Taylor M Weis, Shannon Hough, Haritha G. Reddy, Stephanie Daignault-Newton, Gregory P. Kalemkerian> ;Journal of Oncology Pharmacy Practice. 2020 Apr 1
19 citations
Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
Angel Qin, Haritha G. Reddy, Frank Weinberg, Gregory P. Kalemkerian> ;Expert Opinion on Pharmacotherapy. 2020 Mar 12
50 citations
High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.
Mina Zeinali, Maggie Lee, Arthi Nadhan, Anvya Mathur, Casey Hedman, Eric Lin, Ramdane Harouaka, Max S. Wicha, Lili Zhao, Nallasivam Palanisamy, Mathias Hafner, Rishind...> ;Cancers. 2020 Jan 3
140 citations
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel, Nathan A. Pennell, Mary J. Fidler, Balazs Halmos, Philip Bonomi, James P. Stevenson, Bryan J. Schneider, Ammar Sukari, Jaclyn Ventimiglia, Wei Chen...> ;Journal of Thoracic Oncology. 2018 Sep 1
20 citations
Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer
Peter G. Hawkins, Yilun Sun, Robert T. Dess, William C. Jackson, G. Sun, Nan Bi, Muneesh Tewari, James A. Hayman, Gregory P. Kalemkerian, Shirish M. Gadgeel, Theodore ...> ;Journal of Cancer Research and Clinical Oncology. 2019 Mar 28
25 citations
The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer.
Najwa El Kadi, Luo Wang, April Davis, Hasan Korkaya, Alexander Cooke, Varun Vadnala, Noah A. Brown, Bryan L. Betz, Marilia Cascalho, Gregory P. Kalemkerian, Khaled A. ...> ;Cancer Research. 2018 Dec 15
24 citations
Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.
Jianxin Xue, Chengbo Han, Andrew Jackson, Chen Hu, Huan Yao, Weili Wang, James A. Hayman, Weijun Chen, JianYue Jin, Gregory P. Kalemkerian, Martha Matuzsak, S. Jolly, ...> ;Radiotherapy and Oncology. 2019 Apr 1
183 citations
NCCN guidelines® insights: Small cell lung cancer, version 2.2018 featured updates to the NCCN guidelines
Gregory P. Kalemkerian, Billy W. Loo, Wallace Akerley, Albert Attia, Michael F. Bassetti, Yanis Boumber, Roy H. Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. ...> ;Journal of the National Comprehensive Cancer Network. 2018 Oct 1
12 citations
Treatment Options for Relapsed Small-Cell Lung Cancer: What Progress Have We Made?
Angel Qin, Gregory P. Kalemkerian> ;Journal of Oncology Practice. 2018 Jun 12
Join now to see all

Journal Articles

The EGFR T790M Mutation Is Acquired Through AICDA-Mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung Cancer
Gregory P Kalemkerian, Khaled A Hassan, Clinical Cancer Research

Other

Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer
Kalemkerian GP, Baldini EH
http://www.uptodate.com/contents/chemoradiotherapy-for-the-initial-treatment-of-limited-stage-small-
UpToDate, Wolters Kluwer Health - 2013-03-18